Ansimar (doxofylline) / ICE GROUP, Alitair Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   5 Trials   5 Trials   71 News 
  • ||||||||||  Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
    Retrospective data, Review, Journal:  Efficacy and safety profile of doxofylline in asthma: a meta-analysis. (Pubmed Central) -  Sep 12, 2024   
    Subgroup analysis results indicated that the improvement in FEV1 with doxofylline combined with budesonide was superior to that of budesonide combined with montelukast or tiotropium but inferior to that of budesonide plus formoterol combination. Doxofylline treatment significantly reduces the risk of asthma events and adverse events (AEs), demonstrating good safety and longer-term benefits.
  • ||||||||||  Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
    Review, Journal:  A narrative review of theophylline: is there still a place for an old friend? (Pubmed Central) -  Jun 17, 2024   
    Moreover, we also aim to determine if there is a rationale for using low-dose theophylline due to its immunomodulatory and anti-inflammatory effect, or if the future of methylxanthines lies in newly synthesized derivates of theophylline such as bamifylline, or doxofylline...We searched the database since the year 2009 using the MeSH terms "theophylline", "aminophylline", and "methylxanthines" and we included original articles in the English language...There is considerable controversy associated with its use in current medicine, which can be attributed both to its narrow therapeutic range and its mentioned cardiotoxic effect. Herein, we summarize the current state-of-art of theophylline and its use in human medicine.
  • ||||||||||  Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
    Journal:  Doxofylline as a steroid-sparing treatment in Mexican children with asthma. (Pubmed Central) -  May 7, 2024   
    Rescue medication use decreased significantly in patients receiving D?+?SDB during the first 4-week period. Our results suggest that doxofylline may be a steroid-sparing treatment in asthma, but longer-term, controlled studies are needed to confirm these observations.
  • ||||||||||  Ansimar (doxofylline) / ICE GROUP, Alitair Pharma, Januvia (sitagliptin) / Merck (MSD)
    Journal:  Biochemical evaluation and ligand binding studies on glycerophosphodiester phosphodiesterase from Staphylococcus aureus using STD-NMR spectroscopy and molecular docking analysis. (Pubmed Central) -  Feb 19, 2024   
    After the onset of COPD, doxofylline treatment can achieve better effects than aminophylline treatment. In this study, competent E. coli BL21(DE3)pLysS expression cells were used to express the GDPD enzyme from vancomycin-resistant Staphylococcus aureus (VRSA), which was then purified using size exclusion and anion exchange chromatography...Out of 79 drugs, 13 drugs, including tenofovir (1), adenosine (2), clioquinol (11), bromazepam (12), lamotrigine (13), sulfadiazine (14), azathioprine (15), nicotine (16), sitagliptin PO4 (17), doxofylline (18), clindamycin phosphate (19), gentamycin sulphate (20), and ceftriaxone sodium (21) revealed varying degrees of inhibitory potential with IC50 values in the range of 400
  • ||||||||||  Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
    Bronchodilator effect of oral doxofylline and procaterol in asthma: a randomized crossover study (PS-8 in poster area) -  Jun 17, 2023 - Abstract #ERS2023ERS_3761;    
    Overall, this novel inhalable dual-delivery system may represent a good alternative for the effective treatment of asthma. Epidemiology; General respiratory patient care; Cell and molecular biology; Imaging; Physiology; Pulmonary function testing
  • ||||||||||  Ansimar (doxofylline) / ABC International Pharma
    Journal:  Doxofylline Protects Gram-Negative Pathogens against Antibiotic-Mediated Killing. (Pubmed Central) -  Dec 18, 2021   
    Collectively, our study indicates that doxofylline protects Gram-negative bacteria from antimicrobial lethality by regulating the AcrAB-TolC efflux pump in a TolC-dependent manner and suppressing antibiotic-induced ROS accumulation. These results suggest caution when using antibiotics alongside doxofylline in clinical treatment.
  • ||||||||||  Ansimar (doxofylline) / ABC International Pharma
    Preclinical, Journal:  Effect of Doxofylline on Reducing the Inflammatory Response in Mechanically Ventilated Rats with Chronic Obstructive Pulmonary Disease. (Pubmed Central) -  Sep 15, 2021   
    Compared with group N, the W/D weight ratio and levels of TNF-α, JNK, and p-JNK in the pulmonary tissue decreased in group D (P < 0.05), while the levels of IL-10 increased (P < 0.05). Doxofylline might attenuate pulmonary inflammatory responses in mechanically ventilated rats with COPD, and the JNK/stress-activated protein kinase signaling pathway is involved in doxofylline's inhibition of inflammatory responses in the pulmonary tissue of rats with COPD.
  • ||||||||||  Ansimar (doxofylline) / ABC International Pharma
    Journal:  Effect of terbutaline plus doxofylline on chronic obstructive pulmonary disease. (Pubmed Central) -  Jul 27, 2021   
    Doxofylline might attenuate pulmonary inflammatory responses in mechanically ventilated rats with COPD, and the JNK/stress-activated protein kinase signaling pathway is involved in doxofylline's inhibition of inflammatory responses in the pulmonary tissue of rats with COPD. Terbutaline combined with doxofylline for the treatment of COPD patients can efficiently decrease inflammatory factor levels, and bring them better pulmonary function and quality of life.
  • ||||||||||  Ansimar (doxofylline) / ABC International Pharma, Orient Europharma
    Review, Journal:  The effect of doxofylline in asthma and COPD. (Pubmed Central) -  Oct 24, 2020   
    Clinical studies have shown substantial differences between doxofylline and theophylline. In particular, efficacy/safety profile of doxofylline is better than that of theophylline.
  • ||||||||||  Ansimar (doxofylline) / ABC International Pharma, Orient Europharma
    Journal:  Comparison of anti-inflammatory mechanisms between doxofylline and theophylline in human monocytes. (Pubmed Central) -  Sep 5, 2020   
    In particular, efficacy/safety profile of doxofylline is better than that of theophylline. In conclusion, our data support the growing hypothesis that doxofylline does not have a superimposable mechanism of action compared to theophylline, and this may both explain some differences in the risk/benefit ratio and may direct studies to tailor therapy for patients.
  • ||||||||||  Ansimar (doxofylline) / ICE GROUP, Alitair Pharma
    Trial completion date, Trial initiation date, Trial primary completion date:  EDAI: Effect of add-on Doxofylline on Lung Function in Stable COPD (clinicaltrials.gov) -  Mar 29, 2020   
    P4,  N=78, Not yet recruiting, 
    In conclusion, our data support the growing hypothesis that doxofylline does not have a superimposable mechanism of action compared to theophylline, and this may both explain some differences in the risk/benefit ratio and may direct studies to tailor therapy for patients. Trial completion date: May 2020 --> Nov 2020 | Initiation date: Mar 2020 --> Sep 2020 | Trial primary completion date: Apr 2020 --> Oct 2020
  • ||||||||||  Ansimar (doxofylline) / ABC International Pharma, OEP Philippines
    Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis (TP-17) -  Aug 26, 2019 - Abstract #ERS2019ERS_4485;    
    The method described herein allowed simultaneous determination of the three analytes for the first time and was successfully applied to the pharmacokinetic study of doxofylline and its metabolites after intravenous administration in healthy volunteers. Doxofylline is an effective and safe methylxanthine for the treatment of asthma, with an efficacy/safety profile greater than that of theophylline.
  • ||||||||||  Ansimar (doxofylline) / ABC International Pharma, OEP Philippines
    A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma (TP-15) -  Aug 26, 2019 - Abstract #ERS2019ERS_2680;    
    There were neither serious AEs nor deaths during or shortly after the study. Conclusions This study suggests that doxofylline is effective and well tolerated when administered chronically in asthmatic patients.